Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Function Abnormal

Interventions: Drug: Fexinidazole (HOE239)

First Posted Date: 2022-11-07

Last Posted Date: 2023-06-09

Lead Sponsor: Sanofi

Target Recruit Count: 21

Registration Number: NCT05607173

Locations: 🇧🇬
Investigational Site Number: 100-0001, Sofia, Bulgaria
🇫🇷
Investigational site 250-0001, Rennes, France

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

Phase 2

Recruiting

Conditions: Colitis Ulcerative

Interventions: Drug: SAR443122
Drug: Placebo

First Posted Date: 2022-10-20

Last Posted Date: 2025-05-21

Lead Sponsor: Sanofi

Target Recruit Count: 182

Registration Number: NCT05588843

Locations: 🇺🇸
Om Research LLC- Site Number : 8400014, Lancaster, California, United States
🇺🇸
Gastrointestinal Bioscience Site Number : 8400006, Los Angeles, California, United States
🇺🇸
Agile Clinical Research Trials- Site Number : 8400024, Atlanta, Georgia, United States

and more 92 locations

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: SAR445877
Drug: Cetuximab

First Posted Date: 2022-10-18

Last Posted Date: 2025-04-24

Lead Sponsor: Sanofi

Target Recruit Count: 291

Registration Number: NCT05584670

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute- Site Number : 8400006, Detroit, Michigan, United States
🇺🇸
Fred Hutchinson Cancer Center - 825 Eastlake Ave E- Site Number : 8400010, Seattle, Washington, United States
🇮🇱
Investigational Site Number : 3760004, Be'er Ya'akov, Israel

and more 11 locations

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

Phase 4

Terminated

Conditions: Type 2 Diabetes Mellitus
Renal Impairment

Interventions: Drug: Insulin degludec 100 U/mL
Drug: Insulin glargine 300 U/mL

First Posted Date: 2022-09-23

Last Posted Date: 2023-09-06

Lead Sponsor: Sanofi

Target Recruit Count: 62

Registration Number: NCT05552859

Locations: 🇺🇸
Agile Clinical Research Trials, LLC Site Number: 8400001, Atlanta, Georgia, United States
🇺🇸
Emory University Site Number: 8400032, Atlanta, Georgia, United States
🇺🇸
Advanced Medical Research Site Number: 8400012, Maumee, Ohio, United States

and more 65 locations

A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic

Active, not recruiting

Conditions: Atopic Dermatitis

First Posted Date: 2022-09-06

Last Posted Date: 2025-03-14

Lead Sponsor: Sanofi

Target Recruit Count: 150

Registration Number: NCT05527964

Locations: 🇨🇿
Investigational Site: Bulovka University Hospital, Prague, Czechia

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Dupilumab

First Posted Date: 2022-09-02

Last Posted Date: 2025-02-26

Lead Sponsor: Sanofi

Target Recruit Count: 15

Registration Number: NCT05526521

Locations: 🇺🇸
Washington University School of Medicine- Site Number : 8400004, Saint Louis, Missouri, United States
🇺🇸
Childrens Hospital Medical Center of Akron- Site Number : 8400020, Akron, Ohio, United States
🇺🇸
Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001, Cincinnati, Ohio, United States

and more 12 locations

Real World Study on the Use of Cemiplimab in Adult Patients in UK

Completed

Conditions: Cutaneous Squamous Cell Carcinoma

Interventions: Other: No intervention

First Posted Date: 2022-08-09

Last Posted Date: 2023-07-14

Lead Sponsor: Sanofi

Target Recruit Count: 110

Registration Number: NCT05493826

Locations: 🇬🇧
Sanofi-Aventis UK, Reading, Berkshire, United Kingdom

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

Phase 2

Recruiting

Conditions: Dermatitis Atopic

Interventions: Drug: Amlitelimab
Drug: Topical corticosteroids
Drug: Topical calcineurin inhibitors
Drug: Oral corticosteroids

First Posted Date: 2022-08-08

Last Posted Date: 2025-05-23

Lead Sponsor: Sanofi

Target Recruit Count: 1551

Registration Number: NCT05492578

Locations: 🇺🇸
Clinical Research Center of Alabama - Homewood- Site Number : 8401101, Birmingham, Alabama, United States
🇺🇸
Center for Dermatology and Plastic Surgery- Site Number : 8401119, Scottsdale, Arizona, United States
🇺🇸
Orange County Clinical Trials- Site Number : 8401271, Anaheim, California, United States

and more 136 locations

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

Phase 3

Completed

Conditions: Thrombotic Thrombocytopenic Purpura

Interventions: Drug: Caplacizumab
Drug: Corticosteroids
Biological: anti-CD20 antibody

First Posted Date: 2022-07-21

Last Posted Date: 2025-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 56

Registration Number: NCT05468320

Locations: 🇮🇹
Investigational Site Number : 3800003, Avellino, Campania, Italy
🇮🇹
Investigational Site Number : 3800001, Milano, Lombardia, Italy
🇮🇹
Investigational Site Number : 3800006, Genova, Italy

and more 29 locations

A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: SAR441566
Drug: Placebo

First Posted Date: 2022-07-12

Last Posted Date: 2023-02-15

Lead Sponsor: Sanofi

Target Recruit Count: 38

Registration Number: NCT05453942

Locations: 🇩🇪
Investigational Site Number :2760001, Berlin, Germany

Home Terms & Conditions Privacy Policy